<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02490150</url>
  </required_header>
  <id_info>
    <org_study_id>HDQ-COR-2014-01</org_study_id>
    <nct_id>NCT02490150</nct_id>
  </id_info>
  <brief_title>Corifollitropin Alfa on D5 Versus D7 After Contraceptive Pill</brief_title>
  <official_title>Administration of Corifollitropin Alfa on Day 5 Versus Day 7 After Last Oral Contraceptive Pill in a GnRH (Gonadotropin-releasing Hormone ) Antagonist Protocol in Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Universitari Dexeus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Francisca Martínez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Buenaventura Coroleu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Elisabet Clua</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ignacio Rodríguez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Universitari Dexeus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate if the administration of corifollitropin alfa on day 7 instead of on day 5 after
      pre-treatment with oral contraceptive pill results in a reduced total rFSH (recombinant
      follicle stimulating hormone ) consumption in a GnRH antagonist protocol in donors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>total dosis of rFSH (IU)</measure>
    <time_frame>donors will be followed until the end of stimulation period, an expected average of 15 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Oocyte Donation</condition>
  <arm_group>
    <arm_group_label>Day 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of corifollitropin alfa on Day 5 after last oral contraceptive pill in a GnRH antagonist protocol in donors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Day 7</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of corifollitropin alfa on Day 7 after last oral contraceptive pill in a GnRH antagonist protocol in donors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corifollitropin alfa</intervention_name>
    <arm_group_label>Day 5</arm_group_label>
    <arm_group_label>Day 7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women 18-35 y old ,with regular spontaneous menstrual cycles of 25-30 days length

          -  Who had vaginal sexual intercourse or have no inconvenient for vaginal explorations

          -  Donors can´t have more than 6 children (neither own or after donations)

          -  Not be adopted or being born after a gamete donation pregnancy

          -  BMI between 18-28 kg/m2

          -  Height &gt; 1.55cm

          -  Gynecological and general examination with Pap smear, HIV, HCV (hepatitis C virus ),
             HBV (hepatitis B virus ) and RPR(rapid plasma reagin test ) negative serology, and
             with normal karyotype

          -  No abnormal Psychological profile

          -  Discard any disease: blood disorders, neurodegenerative/psychiatric diseases, Fragile
             X Syndrome, cystic fibrosis carrier, oncology diseases.

          -  Without psychological/psychiatric family history

          -  Will conform to the protocol for the duration of the study

          -  Willingness of adhesion to protocol during the whole study period

          -  Signed informed consent

        Exclusion Criteria:

          -  Polycystic ovarian syndrome

          -  Antral follicle count &gt; 20

          -  Hypersensitivity to the active substance or any of the excipients

          -  Abnormal vaginal bleeding of unknown ethiology

          -  Presence of ovarian cysts or increased size ovaries

          -  History of ovarian hyperstimulation syndrome

          -  Previous controlled ovarian stimulation cycle with more than 30 follicles ≥ 11mm

          -  Previous abdominal surgery that contraindicated the practice of follicular puncture

          -  HIV, HCV, HBV positive serology in women or partner

          -  Important systemic diseases that could interfere with gonadotrophin treatment (ovarian
             and hypothalamic tumors…)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Quiron Dexeus</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Blockeel C, Polyzos NP, Derksen L, De Brucker M, Vloeberghs V, van de Vijver A, De Vos M, Tournaye H. Administration of corifollitropin alfa on Day 2 versus Day 4 of the cycle in a GnRH antagonist protocol: a randomized controlled pilot study. Hum Reprod. 2014 Jul;29(7):1500-7. Epub 2014 May 9.</citation>
    <PMID>24813196</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2015</study_first_submitted>
  <study_first_submitted_qc>July 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2015</study_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut Universitari Dexeus</investigator_affiliation>
    <investigator_full_name>Ignacio Rodriguez</investigator_full_name>
    <investigator_title>MD.</investigator_title>
  </responsible_party>
  <keyword>Corifollitropin alfa</keyword>
  <keyword>Stimulation protocol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Contraceptives, Oral, Combined</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

